Coherus BioSciences (CHRS) CHS-1701 Follow-on Study Met All co-Primary Endpoints
Tweet Send to a Friend
Coherus BioSciences, Inc. (Nasdaq: CHRS) reported topline results from its follow-on pharmacokinetic and pharmacodynamic (PK/PD) clinical study of CHS-1701, a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
